Keywords: Oxford BioMedica, Mayo Clinic, Glaucoma, R&D, Sanofi

Oxford BioMedica in glaucoma R&D accord with Mayo Clinic

Article | 31 October 2011

Print This

UK-based Oxford BioMedica (LSE: OXB) has entered into an R&D collaboration with the USA’s Mayo Clinic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in